Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Qualigen Therapeutics, Inc. - Common Stock (NQ:QLGN)

2.860 +0.010 (+0.35%)
Streaming Delayed Price Updated: 2:59 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Qualigen Therapeutics, Inc. - Common Stock

Myseum (NASDAQ: MYSE) CEO Darin Myman Highlights Privacy-Driven Future of Social Media – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
Faraday Future Announces Closing of Strategic $41 Million Investment in Qualigen Therapeutics (NASDAQ: QLGN) to Accelerate its Dual-Flywheel & Dual-Bridge Eco Strategy
From Faraday Future
Via GlobeNewswire
Wall Street Eyes Synergy CHC (NASDAQ: SNYR) After Power Moves to Expand FOCUSfactor® Energy Drinks in $100B+ Market – More Stocks Inside
Via AB Newswire
Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) for Crypto Business Through PIPE Transaction
From Faraday Future
Via GlobeNewswire
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG
Via AB Newswire
Lifecore Biomedical Announces Cooperation Agreement with 22NW
Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board 
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)
JUPITER, FL - (NewMediaWire) - April 16, 2024 - Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”)... 
Via TheNewswire.com
Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
From Qualigen Therapeutics, Inc.
Via GlobeNewswire
Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors
From Qualigen Therapeutics, Inc.
Via GlobeNewswire
Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split
From Qualigen Therapeutics, Inc.
Via GlobeNewswire
Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Qualigen Therapeutics, Inc.
Via GlobeNewswire
Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute
From Qualigen Therapeutics, Inc.
Via GlobeNewswire
Qualigen Therapeutics to Present at LD Micro Main Event XV
From Qualigen Therapeutics, Inc.
Via GlobeNewswire
Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium
From Qualigen Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.